Thyrocare Q4 FY26 Earnings Call Transcript Released
Thyrocare Technologies released its Q4 FY26 earnings call transcript. The company reported consolidated revenue of ₹224 crore for Q4 FY26, a 20% year-on-year growth. For FY26, consolidated revenue stood at ₹829 crore, up 21%. Profit after tax for FY26 was ₹163 crore, an 81% increase. The company recommended a final dividend of ₹7 per equity share.
The transcript provides detailed insights into the company's performance, strategic initiatives, and future outlook, which are material for investors and analysts.
The announcement is a transcript of an earnings call, which is a routine disclosure. While the financial results discussed were positive, the nature of the announcement itself is informational rather than a specific new development.
Thyrocare Technologies Limited has released the transcript of its post-results earnings conference call held on May 12, 2026, with analysts and investors. The call featured insights from MD & CEO Mr. Rahul Guha, CFO Mr. Vikram Gupta, and other management team members.
During the call, Mr. Guha highlighted significant progress in FY26, including being recognized as a Great Place to Work, receiving two awards from Voice of Healthcare, and onboarding Madhuri Dixit as the brand ambassador. He noted strong growth in the Aarogyam portfolio and a remarkable 66% year-on-year growth for the Jaanch segment. The company also expanded its diagnostic portfolio with allergy testing and initiated genomic testing on May 1, 2026, aiming to make this segment accessible to a broader patient base. Thyrocare processed 210 million tests in FY26, a 23% year-on-year increase, and served 19.2 million patients, up 15% year-on-year. Quality metrics showed a reduction in complaints to 3.06 per million tests, with an average turnaround time of 3.43 hours.
Mr. Rajdeep Panwar, Chief Commercial Officer, reported a 21% year-on-year revenue growth for FY26 and 20% for Q4 FY26, driven by the core pathology business. The franchisee business grew by 18% Y-o-Y for the year and 21% in Q4 FY26, reaching an all-time high of 10,800 active franchisees. The partnership business grew by 32% year-on-year for FY26 and 23% in Q4 FY26, despite a one-off dip attributed to normalized pricing in the insurance segment and a lower scale of camps compared to the previous year.
Dr. Ramesh Kinha, Chief Operating Officer, detailed the expansion of the lab network to 40 labs in India and one in Tanzania, with seven new labs opened in FY26. He also highlighted the strengthening of the test portfolio with additions like Phadia-based allergy testing, histopathology, and next-generation sequencing. The company is focusing on precision diagnostics and translating diagnostic data into clinical insights, citing a fever study and the Bharat Aarogyam Score study. Patient experience improvements include enhanced complaint management, reduced resolution times, and faster report delivery.
Mr. Vikram Gupta, Chief Financial Officer, announced strong financial performance for FY26. Standalone revenue reached ₹774 crores, and consolidated revenue stood at ₹829 crores, both showing a 21% year-on-year growth. EBITDA for the year was ₹262 crores, and profit after tax was ₹163 crores, an 81% year-on-year increase. The company reported net cash and investments of over ₹230 crores with zero debt as of March 31, 2026. The Board of Directors recommended a final dividend of ₹7 per equity share for the year ended March 31, 2026.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.